Key result
CRELD2 protein therapy improves cardiac function after MI by promoting microvessel formation.
Answers are grounded in this paper and cite their sources.
Tissue repair after myocardial infarction (MI) is guided by autocrine and paracrine-acting proteins. Deciphering these signals and their upstream triggers is essential when considering infarct healing as a therapeutic target. Here we perform a bioinformatic secretome analysis in mouse cardiac endothelial cells and identify cysteine-rich with EGF-like domains 2 (CRELD2), an endoplasmic reticulum stress-inducible protein with poorly characterized function. CRELD2 was abundantly expressed and secreted in the heart after MI in mice and patients. Creld2-deficient mice and wild-type mice treated with a CRELD2-neutralizing antibody showed impaired de novo microvessel formation in the infarct border zone and developed severe postinfarction heart failure. CRELD2 protein therapy, conversely, improved heart function after MI. Exposing human coronary artery endothelial cells to recombinant CRELD2 induced angiogenesis, associated with a distinct phosphoproteome signature. These findings identify CRELD2 as an angiogenic growth factor and unravel a link between endoplasmic reticulum stress and ischemic tissue repair.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) studied Myocardial infarction. CRELD2 protein therapy vs. Control (Creld2-deficient, neutralizing antibody, or untreated wild-type) was evaluated on Heart function and microvessel formation. CRELD2 protein therapy improved heart function after myocardial infarction, whereas CRELD2 deficiency or neutralization impaired microvessel formation and caused severe postinfarction heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: